Advertisement
Screener

Lite Strategy, Inc. (LITS) Increase (Decrease) in Receivables

2.8 / 5 stars · 68/120 Roast Me

Lite Strategy, Inc. Increase (Decrease) in Receivables

Lite Strategy, Inc. (LITS) reported Increase (Decrease) in Receivables of -$2.21 million for the 6-month period ending 2020-12-31, per its 10-Q filed 2021-02-04.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInReceivables · last filed 2021-02-04

  • Lite Strategy, Inc. increase (decrease) in receivables for the quarter ending 2020-12-31 was $283.00K.
  • Lite Strategy, Inc. increase (decrease) in receivables for the quarter ending 2020-09-30 was -$2.49M, a 863.19% decline year-over-year.
  • Lite Strategy, Inc. increase (decrease) in receivables for the quarter ending 2020-06-30 was $2.53M.
  • Lite Strategy, Inc. increase (decrease) in receivables for the quarter ending 2020-03-31 was -$22.00K, a 466.67% decline year-over-year.
  • Lite Strategy, Inc. increase (decrease) in receivables for fiscal 2020 was $2.60M.
  • Lite Strategy, Inc. increase (decrease) in receivables for fiscal 2019 was -$82.00K.
Period endIncrease (Decrease) in Receivables 3 monthIncrease (Decrease) in Receivables 6 monthIncrease (Decrease) in Receivables 9 monthIncrease (Decrease) in Receivables 12 month
2020-12-31$283.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-04
-$2.21M
10-Q · filed 2021-02-04
$326.00K
derived: sum of 3 quarters · filed 2021-02-04
$304.00K
derived: sum of 4 quarters · filed 2021-02-04
2020-09-30-$2.49M
10-Q · filed 2020-11-10
$43.00K
derived: sum of 2 quarters · filed 2020-11-10
$21.00K
derived: sum of 3 quarters · filed 2020-11-10
-$209.00K
derived: sum of 4 quarters · filed 2021-02-04
2020-06-30$2.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09
$2.51M
derived: sum of 2 quarters · filed 2020-09-09
$2.28M
derived: sum of 3 quarters · filed 2021-02-04
$2.60M
10-K · filed 2020-09-09
2020-03-31-$22.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-07
-$252.00K
derived: sum of 2 quarters · filed 2021-02-04
$74.00K
10-Q · filed 2020-05-07
-$59.00K
derived: sum of 4 quarters · filed 2021-02-04
2019-12-31-$230.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-04
$96.00K
10-Q · filed 2021-02-04
-$37.00K
derived: sum of 3 quarters · filed 2021-02-04
-$31.00K
derived: sum of 4 quarters · filed 2021-02-04
2019-09-30$326.00K
10-Q · filed 2020-11-10
$193.00K
derived: sum of 2 quarters · filed 2020-11-10
$199.00K
derived: sum of 3 quarters · filed 2020-11-10
$113.00K
derived: sum of 4 quarters · filed 2020-11-10
2019-06-30-$133.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09
-$127.00K
derived: sum of 2 quarters · filed 2020-09-09
-$213.00K
derived: sum of 3 quarters · filed 2020-09-09
-$82.00K
10-K · filed 2020-09-09
2019-03-31$6.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-09
-$80.00K
derived: sum of 2 quarters · filed 2019-05-09
$51.00K
10-Q · filed 2019-05-09
2018-12-31-$86.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07
$45.00K
10-Q · filed 2019-02-07
2018-09-30$131.00K
10-Q · filed 2018-11-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
Grace Therapeutics, Inc. (GRCE)$0.046B-1.83
Xilio Therapeutics, Inc. (XLO)United States$0.052B
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Serina Therapeutics, Inc. (SER)United States$0.054B-2.35
Clene Inc. (CLNN)United States$0.054B-1.99
HERON THERAPEUTICS, INC. /DE/ (HRTX)United States$0.055B-2.38